SPOTLIGHT: Targeted Genetics study on hold
Seattle-based Targeted Genetics has decided to put its lead drug trial on hold after one of the patients in the study became seriously ill. Researchers have stopped dosing volunteers in the early-stage trial for an experimental therapy for inflammatory arthritis--known as tgAAC94--and patients in the study are being monitored. Analysts noted that it's too early to tell if this is a temporary or permanent setback for Targeted Genetics. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
